Today's diagnostic solution

Accurate differention of SCLC from NSCLC is critical

Routine histopathology is the current standard of lung tumor classification but has demonstrated only limited concordance among different pathologists^1-4. Although considered by many as the favorable method of diagnostics, the accuracy of lung cancer classification by IHC is limited by the variable sensitivity and specificity of each marker⁵. Lung cancers show substantial variation in appearance and differentiation from microscopic field to field and from one histological section to the next. There is also a lack of standardization in interpretation of IHC results, and ancillary techniques are used in order to increase the reliability of the histopathology evaluation.

Variability in the Performance of IHC Markers^6-13

Performance of standard IHC markers overlaps to such a degree that their effectiveness in supporting objective subclassifications of NSCLC has been brought into question.

The shortcomings associated with current lung cancer classification methods point to the need for a highly accurate, objective, reproducible, and standardized classification tool in lung cancer diagnosis.

A single, conclusive test that differentiates SCLC, carcinoid, squamous NSCLC and non-squamous NSCLC is finally available. miRview® lung is a microRNA-based molecular diagnostic test that offers

Accuracy
Speed
Simple interpretation
Quantitative analysis
Objective results
Cutting-edge molecular biology

Stang A, Pohlabeln H, Müller KM, Jahn I, Giersiepen K, Jöckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.
Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst. 2004;96(14):1105-1107.
Feinstein AR, Gelfman NA, Yesner R. Observer variability in the histopathologic diagnosis of lung cancer. Am Rev Respir Dis. 1970;101(5):671-684.
Khayyata S, Yun S, Pasha T, Jian B, McGrath C, Yu G, Gupta P, Baloch Z. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol. 2009:37(3):178-83.
Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer. 2008:113(1):5-21.
Hammar SP. Immunohistology of lung and pleural neoplasms. In: Dabbs D, ed. Diagnostic Immunohistochemistry. 2nd ed. Philadelphia, PA: Churchill Livingstone; 2006:329-403.
Camilo R, Capelozzi VL, Siqueira SA, Del Carlo Bernardi F. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in non-small cell lung carcinomas. Hum Pathol. 2006;37:542-546.
Reis-Filho JS, Simpson PT, Martins A, Preto A, Gärtner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003;443(2):122-132.
Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006;19(3):417-428.
Au NH, Gown AM, Cheang M, et al. p63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol. 2004;12(3):240-247.
Saad RS, Liu YL, Han H, Landreneau RJ, Silverman JF. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol. 2004;35(1):3-7.
Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol. 2002;55(9):662-668.
Tan D, Li Q, Deeb G, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol. 2003;34(6):597-604.